Sevelamer
- Generic Name
- Sevelamer
- Brand Names
- Renagel, Renvela, Sevelamer carbonate Winthrop (previously Sevelamer carbonate Zentiva)
- Drug Type
- Small Molecule
- Chemical Formula
- C6H12ClNO
- CAS Number
- 52757-95-6
- Unique Ingredient Identifier
- 941N5DUU5C
- Background
Sevelamer is a phosphate binding drug used to prevent hyperphosphataemia in patients with chronic renal failure. It is marketed by Genzyme under the trade name Renagel.
- Indication
For the control of serum phosphorus in patients with Chronic Kidney Disease (CKD) on hemodialysis.
- Associated Conditions
- Hyperphosphataemia
- Associated Therapies
- -
A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis
- Conditions
- Interventions
- First Posted Date
- 2018-02-09
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- Ardelyx
- Target Recruit Count
- 1559
- Registration Number
- NCT03427125
- Locations
- 🇺🇸
Site 529, Bronx, New York, United States
🇺🇸Wake Forest School of Medicine, Winston-Salem, North Carolina, United States
DS2330b Alone and With Sevelamer in Patients on Chronic Hemodialysis
- Conditions
- Interventions
- First Posted Date
- 2017-10-10
- Last Posted Date
- 2019-03-25
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 40
- Registration Number
- NCT03305471
- Locations
- 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸DaVita Clinical Research, Minneapolis, Minnesota, United States
🇺🇸Prism Clinical Research, Saint Paul, Minnesota, United States
Effect of Bile Acid Secretion and Sequestration on GLP-1 Secretion
- Conditions
- Interventions
- First Posted Date
- 2015-05-15
- Last Posted Date
- 2017-05-03
- Lead Sponsor
- University Hospital, Gentofte, Copenhagen
- Target Recruit Count
- 15
- Registration Number
- NCT02445508
- Locations
- 🇩🇰
Center for Diabetes Research, Hellerup, Denmark
Effect of Sevelamer on P-cresol Levels in CKD
- First Posted Date
- 2014-07-24
- Last Posted Date
- 2015-02-18
- Lead Sponsor
- Federico II University
- Target Recruit Count
- 200
- Registration Number
- NCT02199444
- Locations
- 🇮🇹
federico II university, department of nephrology, Naples, Italy
Mechanism of Microbiome-induced Insulin Resistance in Humans (Aim2)
- Conditions
- Interventions
- First Posted Date
- 2014-04-30
- Last Posted Date
- 2020-09-11
- Target Recruit Count
- 69
- Registration Number
- NCT02127125
- Locations
- 🇺🇸
Audie L. Murphy VA Hospital, STVHCS, San Antonio, Texas, United States
Mechanism of Microbiome-induced Insulin Resistance in Humans (Aim 1)
- Conditions
- Interventions
- First Posted Date
- 2014-04-28
- Last Posted Date
- 2021-10-15
- Target Recruit Count
- 20
- Registration Number
- NCT02124759
- Locations
- 🇺🇸
Audie L. Murphy VA Hospital, STVHCS, San Antonio, Texas, United States
Sevelamer in Proteinuric CKD
- Conditions
- Interventions
- First Posted Date
- 2013-10-24
- Last Posted Date
- 2015-10-12
- Target Recruit Count
- 53
- Registration Number
- NCT01968759
- Locations
- 🇮🇹
Clinical Research Center for Rare Diseases, Ranica, Bergamo, Italy
🇮🇹Azienda Ospedaliera "Bianchi-Melacrino-Morelli" c/o Ospedali Riuniti U.O. Nefrologia, Dialisi e Trapianto, Reggio Calabria, Italy
Dose-Titration Study of Sevelamer Carbonate in Chronic Kidney Disease (CKD) Patients on Hemodialysis
- Conditions
- Interventions
- First Posted Date
- 2012-11-29
- Last Posted Date
- 2015-03-23
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 205
- Registration Number
- NCT01736150
- Locations
- 🇨🇳
Zhongda Hospital of Southeast University, Nanjing, China
🇨🇳Shanghai Ruijin Hospital, Shanghai, China
🇨🇳Peking Union Medical College Hospital, Beijing, China
An Efficacy and Safety Study of Sevelamer Carbonate in Hyperphosphatemic Pediatric Participants With Chronic Kidney Disease
- Conditions
- Interventions
- First Posted Date
- 2012-04-10
- Last Posted Date
- 2016-07-25
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 101
- Registration Number
- NCT01574326
- Locations
- 🇺🇸
Investigational Site Number 8017, Livingston, New Jersey, United States
🇺🇸Investigational Site Number 8007, Atlanta, Georgia, United States
🇺🇸Investigational Site Number 8009, Greenville, North Carolina, United States
Sevelamer for Reducing Endotoxemia and Immune Activation
- First Posted Date
- 2012-03-05
- Last Posted Date
- 2018-10-11
- Target Recruit Count
- 40
- Registration Number
- NCT01543958
- Locations
- 🇺🇸
Harbor-UCLA Med. Ctr. CRS (603), Torrance, California, United States
🇺🇸Univ. of Miami AIDS CRS (901), Miami, Florida, United States
🇺🇸Massachusetts General Hospital ACTG CRS (101), Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.